We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

DNAVision Orders Europe’s Second and Benelux First HISeq2000™ for Commercial Use

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
DNAVision announces the purchase of Illumina’s new HiSeq 2000™ sequencing platform, which has officially been launched three weeks ago.

Illumina’s latest sequencing system will be installed in Gosselies’facility and implemented in the high quality certifications environment. This latest acquisition will further strengthen DNAVision’s current portfolio of next generation sequencing services on GA IIx and Roche 454.

Initially, DNAVision will employ the HiSeq 2000™ for human genome sequencing projects for its pharmaceutical and medical research customers.

“As DNAVision already has Illumina CSPro certification in place and is the only genomics company in the world to be ISO17025 accredited, CLIA certified, CAP accredited, GLP certified and GMP certified, we are pretty confident that we will produce human genome data with any quality certification requested. We want to be the first company to provide human genome sequencing data deemed suitable for medical purposes and move with this breakthrough technology to personalized medicine” says Jean-Pol Detiffe, CEO of DNAVision. Illumina’s HiSeq 2000™ with the estimated output of 200 GB per run allows us to virtually sequence 2 human genomes at 30x coverage in a week.